December 29, 2025, Medlander (688273.SH)The "Nd:YAG Picosecond Laser Treatment Device" independently developed has been officially approved by the National Medical Products Administration, with the registration number: NMPA Approval 20253092690. This is the 10th picosecond laser treatment device approved in China and the 7th produced domestically.
It is reported that,As of now, those approved in ChinaThe picosecond laser treatment instrument has a total of10 Models, among which,Three imported modelsCynosure's "PicoSure," Syneron's "PicoWay," and WonTech's "Picocare";Seven models made in ChinaThey are KPico by Coherent Laser, PicoV by Wis Medical, "Star Super PicoSecond" PicoPeak by MedLite, "Youthful Super PicoSecond" PS10 by Ander Optoelectronics, "Peninsula White Extreme Light" PicoWell by Peninsula Medical, "Stellar PicoSecond" ForePico by Forelle, and Medlander's "Picosecond Laser Treatment DeviceMedlander asChina Intelligent Pelvic Floor Reproductive Rehabilitation Diagnosis and TreatmentThe leading brand in the industry, focusing onPelvic Floor Treatment DeviceResearch and development, production, sales and service, while providingFemale Reproductive Anti-AgingOverall Solution in the Field。As of now, Medlander has officially formed"The dual-driven industrial ecosystem of 'serious medical + consumer medical'"In the field of rehabilitation, the company's products have covered nearly 9,000 medical institutions across China; in the consumer healthcare field, the company is actively expanding into home-useMedical Devices and Anti-Aging Field, launching private testing + anti-aging, reproductive + facial integrated solutions, and has successively invested inYisu Medical, Aotong Laser, Xiaofu Technology`, Company`The product "Meiji 3D Skin Analyzer" has served over 1,200 top medical aesthetics institutions across China.
Medlander Medical Technology Inc. was founded inIn 2013, Medlander Medical Technology Inc. was established as a provider of physical rehabilitation intervention technology solutions for the entire life cycle of women in China. The company is mainly engaged in the research and development, production, and sales of products related to pelvic floor and postpartum rehabilitation, forming a series of medical pelvic floor, postpartum recovery, and home-use products. It has been successively recognized as a national-level specialized, refined, distinctive, and innovative "little giant" enterprise, a demonstration enterprise of a single product champion in national manufacturing, and successfully listed on the STAR Market on August 11, 2022, with the stock code: 688273.
MedlanderMedlanderBuilding on the foundation of pelvic floor and postpartum rehabilitation, the company further expands into areas such as reproductive rehabilitation, sports rehabilitation, nutrition, and health management, striving to become a world-class healthcare company dedicated to women's health and beauty.It now has product lines including pelvic floor and postpartum rehabilitation equipment, reproductive rehabilitation equipment, consumables and accessories, health management information systems, etc., which are widely used in medical and health fields such as obstetrics and gynecology, pelvic floor rehabilitation, reproductive rehabilitation, urology and proctology, and physical examination.
In the field of postpartum rehabilitation, mainly targeting gynecological and obstetric rehabilitation, postpartum recovery, and the diagnosis and treatment of pelvic floor functional disorders. Products mainly include: biofeedback stimulators, pelvic floor ultrasound, magnetic stimulators, high-frequency evaluation electrosurgical units, pelvic floor trainers, portable postpartum recovery devices, and home-use pelvic floor rehabilitation therapy devices, which are widely used in departments such as gynecology, pelvic floor rehabilitation centers, urology, and proctology in hospitals.In the field of reproductive rehabilitationMainly targeting post-abortion surgery, post-hysteroscopy surgery, infertility, and adjuvant treatment for premature ovarian failure. The products mainly include: biofeedback stimulators, high-frequency evaluation and electrocautery devices, ultrasonic uterine restoration devices, and electro-ultrasound therapy devices, applied in gynecology, obstetrics, reproductive centers, medical cosmetology institutions, and other fields.In the field of sports rehabilitation, mainly targeting motor function disorders and hand function assessment and rehabilitation for people with cerebral palsy and post-stroke. Products mainly include: Finger Joint Rehabilitation Assessment System, Portable Hand Function Rehabilitation Assessment System, Hand Function Magnetic Stimulation System, Biofeedback Stimulator, Portable Biofeedback Stimulator, applied in rehabilitation departments, pediatric rehabilitation departments, neurology departments, orthopedic departments, and geriatric departments.
In addition, Medlander also strengthens the competitiveness of its rehabilitation product line through mergers, acquisitions, and investments.Horizontal Layout in Other Medical Aesthetics and Related Fields. Since 2019, they have successively investedOpex Medical, Yisu Medical, Aotong Laser, Xiaofu Technology, laying out plans for injection-molded parts, female reproductive rehabilitation products, laser equipment, and technology-based skin testing, to establish a foundation for the long-term strategic planning of health and beauty.
On October 24, 2023, Medlander completed the acquisition of 100% equity in Shanghai Aotong Laser.It is reported that Aotong Laser is a high-tech enterprise specializing in the development, production, and operation of laser medical equipment. It is committed to providing comprehensive laser, photon medical, and beauty solutions to users across China and other regions globally, including high-performance equipment, comprehensive technical support, and continuous clinical support.
On January 26, 2024, Medlander completed the acquisition of 55% equity in Hangzhou Xiaofu Technology.It is reported that Xiaofu Technology is a company that has taken the lead in completing the deep integration of imaging acquisition hardware, application software, underlying analysis algorithms, and business scenarios in the fields of 3D facial modeling and AI skin and morphology analysis. It provides customers with integrated medical aesthetics digital diagnosis and solutions. Its core product, "Meiji 3D Skin Analyzer," now serves more than 1,200 leading medical aesthetics institutions across China.
On June 6, 2024, the overall structural construction of Medlander Medical Technology Inc.'s headquarters R&D and production base project was completed, achieving the topping out of the main structure.It is reported that the construction of Medlander's headquarters R&D and production base officially started on December 31, 2022. Covering an area of 44 mu, with a total building area of 90,000 square meters and a total investment of over 500 million yuan, the park integrates R&D, production, assembly, debugging, warehousing, office, and living facilities.
July 5, 2024Medlander andBeautiful Land signs strategic cooperation agreement, Both parties will join hands to deepen cooperation in sharing R&D resources for women's gynecological anti-aging, and jointly promote the industry to a higher level. It is reported that both partiesWill share gynecological anti-aging research achievements, technologies, and market information, promote industry technological innovation and industrial upgrading, and provide female customers with more professional and personalized solutions.
On February 28, 2025, Medlander's self-developed Class II "Ultrasonic Therapy Device" was officially approved by the Jiangsu Provincial Medical Products Administration., Registration Certificate No.: Su Medical Device Registration Approval 20252090332. It is reported that, as of now in China, two Class II ultrasound therapy devices for "skin tightening, lifting, and wrinkle removal" have been approved, respectively.Exclusively distributed by Jingyan BiotechMFU pro"MeramayUltrasonic Scalpel(Yu Medical Device Registration Approval 20242090073) andGuizhou Polida MedicalBolidaPolida®"Platinum Ultrasound Cannon"(Qian Medical Device Registration Approval 20242090048),Medlander's "Ultrasonic Therapy Device" is approved in China.The 3rd-Generation Ultrasound Therapy Device for Medical Aesthetics Compliance Indications。
On March 12, 2025, Medlander's reproductive anti-aging brand Weizhilan®Strategic Cooperation Release and Unveiling Ceremony Held at Yuansong Medical Aesthetics in Chengdu with Yuansong Group"Chengdu Yuansong Training Benchmark Base", marking the private medical aesthetics industry from"Technological Iteration" Moves Towards a New Stage of "Ecosystem Co-construction".On October 23, 2025, Medlander released its Q3 2025 financial report, with the company achieving a revenue of 344 million yuan, a year-on-year increase of 4.01%; net profit attributable to shareholders was 95.9987 million yuan; of which, Q3 achieved a revenue ofRMB 103 million, increased by 0.4% year-on-year; net profit attributable to parent company was RMB 32.08 million, increased by 36.7% year-on-year.
